Transcription factor FoxO1 Mediates Adaptive Increase in Akt Activity and Cell Survival During BCR Inhibitor Therapy in CLL.

• Authors: MRÁZ Marek; ONDRIŠOVÁ Laura; ŠEDA Václav; HOFERKOVÁ Eva; CHIODIN G.; HLAVÁČ Kryštof; KOŠŤÁLOVÁ Lenka; MLADONICKÁ PAVLASOVÁ Gabriela; FILIP Daniel; ZENI Pedro; OPPELT Jan; PANOVSKÁ Anna; PLEVOVÁ Karla; POSPÍŠILOVÁ Šárka; ŠIMKOVIČ M.; VRBACKÝ F.; LYSÁK Daniel; FERNANDES SM.; DAVIDS A.; MAIQUES-DIAZ A.; CHARALAMPOPOULOU S.; MARTIN-SUBERO J.; BROWN J.; DOUBEK Michael; FORCONI F.; MAYER Jiří
• Year of publication: 2023
• Type: Conference abstract
• MU Faculty or unit: Central European Institute of Technology

Attached files

• Transcription_factor_FoxO1_mediates_adaptive_increase_in_Akt_activity_and_cell_survival_during_BCR_inhibitor_therapy_in_CLL.pdf

• Description: In this interview, Marek Mráz, PhD, Central European Institute of Technology, Brno, Czech Republic, outlines a study on resistance of chronic lymphocytic leukemia (CLL) to BCR inhibitor therapy through increased activity of the FoxO1-Rictor-pAkt axis. This highlights the potential of FoxO1 as a novel therapeutic target, with testing of a FoxO1 inhibitor in vitro showing its ability to kill CLL cells.This interview was recorded at the biennial International Workshop on Chronic Lymphocytic Leukemia (iwCLL) 2023 meeting, held in Boston, MA.

Related projects

• ÚLOHA MICRORNA A JEJICH CÍLOVÝCH MOLEKUL V TRANSFORMACI FOLIKULÁRNÍHO LYMFOMU A AGRESIVITĚ CHRONICKÉ LYMFOCYTÁRNÍ LEUKÉMIE
• Signaling propensity in the microenvironment of B cell chronic lymphocytic leukemia
• National institute for cancer research
• Nové přístupy ve výzkumu, diagnostice a terapii hematologických malignit X